{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:15:07Z","timestamp":1760220907188,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hfc.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:00:13Z","timestamp":1753156813000},"page":"549-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Medical Therapy in Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"21","author":[{"given":"Jung-Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyeong-Hyeon","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eui-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hfc.2025.06.005_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3750879","article-title":"Disparities in the diagnosis of hypertrophic obstructive cardiomyopathy: a narrative review of current literature","volume":"2018","author":"Burns","year":"2018","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.hfc.2025.06.005_bib3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib4","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American heart Association\/American College of Cardiology Joint Committee on Clinical Practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2025.06.005_bib6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib7","article-title":"Stable rates of obstructive hypertrophic cardiomyopathy in a contemporary era","volume":"8","author":"Butzner","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023313","article-title":"Differences in characteristics and outcomes between patients with hypertrophic cardiomyopathy from Asian and European centers","volume":"11","author":"Tjahjadi","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hfc.2025.06.005_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024792","article-title":"Prognostic implication of mitral valve disease and its progression in east asian patients with hypertrophic cardiomyopathy","volume":"12","author":"Kim","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hfc.2025.06.005_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/eurheartj\/ehv120","article-title":"Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction","volume":"36","author":"Dass","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2025.06.005_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1532-429X-14-76","article-title":"Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction","volume":"14","author":"Ellims","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.hfc.2025.06.005_bib13","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","article-title":"Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging","volume":"115","author":"Petersen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib14","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s10554-023-02894-y","article-title":"Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy","volume":"39","author":"Coleman","year":"2023","journal-title":"Int J Cardiovasc Imag"},{"key":"10.1016\/j.hfc.2025.06.005_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.hfc.2025.06.005_bib16","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"Beta Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib19","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.51.5.523","article-title":"Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function","volume":"51","author":"Anderson","year":"1984","journal-title":"Br Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9149(96)00336-0","article-title":"Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy","volume":"78","author":"Betocchi","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib23","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cjco.2024.03.006","article-title":"Does disopyramide still have a place in the management of obstructive hypertrophic cardiomyopathy?","volume":"6","author":"Corriveau","year":"2024","journal-title":"CJC Open"},{"key":"10.1016\/j.hfc.2025.06.005_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2025.06.005_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM Randomized Clinical Trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2024.06.025","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in VALOR-HCM Trial","volume":"84","author":"Desai","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib29","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Investigators. Phase 2 Study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib31","article-title":"Safety and efficacy of mavacamten and aficamten in patients with hypertrophic cardiomyopathy","volume":"14","author":"Davis","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hfc.2025.06.005_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hfc.2025.06.005_bib33","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in Symptomatic Nonobstructive Hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2025.06.005_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.hfc.2025.06.005_bib35","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.123.064153","article-title":"Myocardial neprilysin is increased in hypertrophic cardiomyopathy","volume":"148","author":"Armstrong","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/clc.23346","article-title":"Design of the SILICOFCM study: effect of sacubitril\/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy","volume":"43","author":"Tafelmeier","year":"2020","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hfc.2025.06.005_bib41","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2025.06.005_bib42","doi-asserted-by":"crossref","first-page":"C155","DOI":"10.1093\/eurheartjsupp\/suad042","article-title":"Stage-specific therapy for hypertrophic cardiomyopathy","volume":"25","author":"Argiro","year":"2023","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.hfc.2025.06.005_bib43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","article-title":"Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy","volume":"31","author":"Melacini","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2025.06.005_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04817-8","article-title":"Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy","volume":"608","author":"Chaffin","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.hfc.2025.06.005_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","article-title":"Genetic pathogenesis of hypertrophic and dilated cardiomyopathy","volume":"14","author":"Garfinkel","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.hfc.2025.06.005_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2025.06.005_bib48","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/heartjnl-2016-310720","article-title":"Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy","volume":"103","author":"Lee","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.hfc.2025.06.005_bib49","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2025.06.005_bib50","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713625000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:39:31Z","timestamp":1760218771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713625000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1551713625000546"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2025.06.005","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Medical Therapy in Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}